Page 93 - MemoriaEHD-Eng

www.ciberehd.org

• r-g M, p r, a J, s r, g-s J, D M, C J, C-
Most relevant oMeroóMezLaNasMpuerooLàarCíaaMaNiegoiagorespoa
LLeJa JL, turNes J.. Meta-analysis: pegylated interferon α-2a achieves higher early vi-
scientific rological responses than α-2b in chronic hepatitis C.Aliment Pharmacol Ther. 2013;.

articles
• rivas p, herrero MD, poveDa e, MaDeJóN a, treviño a, gutiérrez M. Hepatitis B, C, and D
and HIV infections among immigrants from Equatorial Guinea living in Spain.Am J

Trop Med Hyg. 2013 Apr;88(4):789-94.

• garCía-saMaNiego J, roMero M, graNaDos r, aLeMáN r, Jorge JuaN M, suárez D. Factors
associated with early virological response to peginterferon-α-2a/ribavirin in chronic

hepatitis C.World J Gastroenterol. 2013 Mar 28;19(12):1943-52.

• aNDraDe rJ, garCía-saMaNiego J. [Biochemical and pharmacological features of telapre-
vir].Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:2-6.

• t J, r-g M, p r, s r, g-s J, D M. Pharma-
urNesoMeroóMezLaNasoLàarCíaaMaNiegoiago
coeconomic analysis of the treatment of chronic hepatitis C with peginterferon al- á
fa-2a or peginterferon alfa-2b plus ribavirin in Spain.Gastroenterol Hepatol. 2013

Nov;36(9):555-64.

Highlights
FINANCIAL SUPPORT. í
í
• Public research projects.

- Identification of treatment-resistant HCV variants against telaprevir or boceprevir
therapy by using cold-PCR technique. Application in monitoring antiviral response.

PI: Javier Garca-Samaniego. FINANCING SOURCES: FISS PI12/02146.
•
Private financing research projects. óó
- Genetic and epigenetic analysis of asymptomatic HBV carriers. Implications in the

therapeutic decisions. PI: Antonio Madejón. FINANCING SOURCES: Gilead S.A.

- Performance evaluation of a qPCR based point-of-care test (POCT) for blood-borne
viral infections: HCV, HIV and HTLV. PI: Antonio Madejón, Berta Rodes and Carlos

MOST RELEVANT PARTICIPATIONS IN COLABORATIVE PROJECTS.
íí
• Epigenetic mechanisms induced by hepatitis C virus; involvement in the evolution

of fibrosis and development of hepatocellular carcinoma. PI: Javier García-Sama-
niego. CIBERehd GROUPS: Dr. Esteban Domingo. EXTERNAL COLABORATORS: Dr.

Snchez-Pacheco (Medicine Faculty, Biochemistry Department, UAM).
ó

• Automate High-resolution HCV subtyping and detection of resistant mutations and
translate into a routine diagnostic laboratory. IPs: J.Quer, F.Rodríguez-Frias. CIBER

GROUPS: JI.Esteban, R.Esteban, X.Forns, J.Garcia-Samaniego.

• Epigenetic modulation of chronic hepatitis c progression to hepatocellular carcino-
ma: role of histone deacetylases genetic variants. PI: Paloma Sanz Cameno. CIBE-

Rehd GROUPS: Dr. Salmern, Dr. Garca-Samaniego.
•
Identification and validation of angiogenic biomarkers of chronic hepatitis c progres- 13
sion to cirrhosis and hepatocellular carcinoma. PI: Dr. Paloma Sanz Cameno. CIBE- 20
T
Rehd GROUPS: Dr. Salmern, Dr. Garca-Samaniego, Dr. Forns, Dr. Pérez del Pulgar.
OR
• P
HeapiC-based Nationwide point-of-care concerted action for HCV screening and RE
“treatment as prevention and cure”. PI: Dr. J.I.Esteban. PARTICIPATING GROUPS: L
A
All groups of the CIBEREHD-VHP, ABL.
NU
• N
Pharmacogenomics in triple therapy: Genome Wide Association Study (GWAS) in A
Hepatitis C patients treated with peginterferon + ribavirin + protease inhibitor: D /
H
Safety and Efficacy. PI: Dr. Manuel Romero-Gmez. PARTICIPATING GROUPS: All E
groups of the CIBEREHD – Viral hepatitis program
ER
IB
CLINICAL TRIALS.
C

Dr. Javier Garca-Samaniego is the principal investigator of 18 active cluinical trials in 93
the Hospital carlos III.